Loading...
•
Dec 31, 2020
Eagle Q4 2020 Earnings Report
Reported strong earnings with adjusted non-GAAP earnings growth.
Key Takeaways
Eagle Pharmaceuticals reported a strong earnings year with a 36% year-over-year growth, despite challenges from the COVID-19 pandemic. The company's balance sheet remains healthy, supporting development programs and future growth. Key pipeline products like vasopressin, fulvestrant, and Ryanodex for nerve agent exposure show significant opportunities.
Q4 2020 net income was $0.62 per basic and $0.60 per diluted share.
Adjusted non-GAAP net income for Q4 2020 was $0.98 per basic and $0.96 per diluted share.
Total revenue for Q4 2020 was $49.9 million.
Gross Margin was 75% during the fourth quarter of 2020.
Revenue by Segment
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...